Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Oncol. 2012 Apr;39(2):139-44. doi: 10.1053/j.seminoncol.2012.01.011.

Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.

Author information

  • 1Moffitt Cancer Center, Tampa, FL 33612, USA. Ragini.kudchadkar@moffitt.org

Abstract

Basal cell carcinoma (BCC) is the most common tumor of the skin and can result in significant morbidity as well as costs. The discovery of aberrant Hedgehog (HH) signaling in patients with genetic propensity to develop BCCs has resulted in a better understanding of the genetic abnormalities leading to the development of BCC. The current state of knowledge with regard to the genetics of BCC is discussed. Existing therapies are reviewed, in particular new targeted therapies to the HH signaling pathway that have resulted in a landmark breakthrough for patients with refractory BCC. Data from recent and ongoing trials are presented.

Published by Elsevier Inc.

PMID:
22484185
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk